Contributions of flow cytometry to the analysis of the myelodysplastic syndrome

Clinics in Laboratory Medicine

Volumn 21, Issue 4, 2001, Pages 811-828

  Miller, D T ^a   Stelzer, G T ^a  

^a Esoterix Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANALYTIC METHOD; BLAST TRANSFORMATION; CASE REPORT; CYTOGENETICS; EARLY DIAGNOSIS; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; INCIDENCE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM;

AGED; CYTOGENETIC ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; UNITED STATES;

EID: 0035213260     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes
2. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes
3. Cytogenetic abnormalities are associated with immunophenotypic changes in refractory anemia
4. Glutathione S-transferase gene deletions in myelodysplasia
5. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes
6. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes
7. Epidemiological and etiological aspects of myelodysplastic syndromes
8. Increasing incidence of myelodysplastic syndromes: Real or fictitious?
9. Multiparameter flow-FISH: A new approach to simultaneously measure telomere length in leukocyte subsets
10. Immune mechanisms and modulation in MDS
11. World Health Organization classification of the acute leukemias and myelodysplastic syndrome
12. Proposals for the classification of myelodysplastic syndromes
13. Collapse of mitochondrial potential as a marker of early apoptosis in myelodysplastic syndromes
14. Mitochondria and cell death
15. Telomere states and cell fates
16. Incidence and role of apoptosis in myelodysplastic syndrome: Morphological and ultrastructural assessment
17. Time-course expression of polypeptides carrying blood group antigens during human erythroid differentiation
18. Telomere length in myelodysplastic syndromes
19. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro
20. Abnormal patterns of expression of CD16 (FcRγIII) and CD11b(CRIII) antigens by developing neutrophils in the bone marrow of patients with myelodysplastic syndrome
21. CD34+/CD36 - Cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation
22. The supportive effect of erythropoietin and mast cell growth factor on CD34+/CD36 - Sorted bone marrow cells of myelodysplasia patients
23. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin
24. MtDNA mutations associated with sideroblastic anaemia cause a defect of mitochondrial cytochrome c oxidase
25. Lecam/Icam ration identifies a distinct pattern on normal and myodysplastic syndromes (MDS) bone marrow CD34+ cells
26. X-inactivation analysis in the 1990s: Promise and potential problems
27. Clinical significance of CD55 and CD59 deficiency in patients with primary myelodysplastic syndrome
28. Clonal haemopoiesis in normal elderly women: Implications for the myeloproliferative disorders and myelodysplastic syndromes
29. Apoptosis is a common histopathological finding in myelodysplasia: The correlate of ineffective haematopoiesis
30. Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes
31. Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis
32. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: Relation to disease progression
33. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome
34. The impact of the immunophenotype on prognosis in myelodysplastic syndromes patients: A multivariate analysis
35. Mitochondria as the central control point of apoptosis
36. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes
37. Myelodysplastic syndromes
38. Surface marker abnormalities in myelodysplastic syndromes
39. Granulocytic surface marker abnormalities are detected only in patients with myelodysplastic syndrome and patients with Shwachman Diamond syndrome but not other bone marrow failure syndromes
40. The Lutheran blood group glycoproteins, the erythroid receptors for laminin, are adhesion molecules
41. Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome
42. Immunophenotypic clustering of myelodysplastic syndromes: Results of a multicentric study
43. Ineffective erythropoiesis in myelodysplastic syndromes: Correlation with Fas expression but not with lack of erythropoietin receptor signal transduction
44. Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry
45. Flow cytometric method for enumeration and classification of reactive granulocyte populations
46. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes
47. Validation of the WHO proposals for a new classification of the myelodysplastic syndromes: Analysis of 1640 patients
48. A role for tumour necrosis factor-α: Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome
49. International scoring system for evaluating prognosis in myelodysplastic syndromes
50. Apoptosis and its role in the myelodysplastic syndromes: Implications for disease natural history and treatment
51. Prognostic scoring systems for risk assessment in myelodysplastic syndromes
52. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival
53. Immunological abnormalities in myelodysplastic syndromes
54. Myelodysplasia
55. A final decision model for treating the anemia of myelodysplastic syndromes (MDS) with EPO+ G-CSF
56. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model
57. Primary vs. secondary neoplasia-associated chromosomal abnormalities - Balanced rearrangements vs. genomic imbalances?
58. High expression of phosphatidylserine in MDS, secondary AML and normal progenitors
59. Mitochondrial control of cell death
60. Is apoptosis a massive process in myelodysplastic syndromes?
61. Proliferation and apoptosis in leukemias and myelodysplasia as determined by PCNA level and caspase 3 activity
62. The mitochondrion in cell death control: Certainties and incognita
63. Flow cytometric analysis of human bone marrow: I. Normal erythroid development
64. Incomplete apoptosis in acquired idiopathic sideroblastic anemia (IASA) favors the hypothesis of a maturation defect leading to ineffective erythropoiesis
65. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor V-beta profiles
66. Detection of TNFα expression in the bone marrow and determination of TNFα production of peripheral blood mononuclear cells in myelodysplastic syndrome
67. A guide to risk assessment in the primary myelodysplastic syndrome
68. Evidence for involvement of tumor necrosis factor alpha in apoptotic death of bone marrow cells in apoptotic death of bone marrow cells in myelodysplastic syndromes
69. Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes
70. The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows
71. HLA DR15 (DR2) is over-represented in myelodysplastic syndrome (MDS) and is associated with response to immunosuppression
72. Exposure to occupational and environmental factors in myelodysplastic syndromes: Preliminary results of a case-control study
73. Altered expression of effector cell molecules on neutrophils in myelodysplastic syndrome
74. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes
75. Comparative multi-color flow cytometric analysis of cell surface antigens in marrow hematopoietic progenitors between refractory anemia and aplastic anemia
76. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins
77. The role of apoptosis, proliferation, and the bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS
78. Erythroid cells adhesion molecules Lutheran and LW in health and disease
79. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration
80. DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS)
81. Marrow cytokine transcripts and the secondary hematologic disorders
82. Glutathione S transferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens
83. Altered oncogene expression and apoptosis in myelodysplastic syndrome marrow cells
84. Myelodysplastic syndrome: A search for minimal diagnostic criteria
85. Apoptosis in bone marrow samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
86. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes: Identification of a subgroup of responders
87. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria
88. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes
89. Refractory cytopenia with multilineage dysplasia: Further characterization of an 'unclassifiable' myelodysplastic syndrome
90. A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies
91. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome
92. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: Apoptotic cells recovered from high-density fraction of bone marrow aspirates
93. The expression of human blood group antigens during erythropoiesis in a cell culture system
94. The human mitochondrial NADH: Ubiquinone oxidoreductase 51-kDa subunit maps adjacent to the glutathione S-transferase P1-1 gene on chromosome 11q13
95. Phenotypic changes in cytogenetically abnormal myelodysplastic syndromes
96. Apoptosis in myelodysplastic syndromes (MDS): Differential involvement of marrow cells in early versus advanced cases and correlation with expression of apoptosis-related genes
97. Apoptosis in patients with myelodysplastic syndromes: Differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes
98. Programmed cell death (PCD) in the marrow of patients with myelodysplastic and myeloproliferative diseases concerns almost exclusively CD34+ cells
99. Myelodysplasia and apoptosis: New insights into ineffective erythropoiesis
100. Occult B cell malignancies can be detected by three-color flow cytometry in patients with cytopenias
101. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure
102. Biologic and genetic features of the myelodysplastic syndromes
103. Molecular genetic features of myelodysplastic syndromes (MDS)
104. Apoptosis and its significance in MDS: Controversies revisited
105. New insights into the pathophysiology of acquired cytopenias